Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients

Koshi Hashimoto, Tetsuya Tagami, Hajime Yamakage, Kazuya Muranaka, Masashi Tanaka, Shinji Odori, Shigeo Kono, Akira Shimatsu, Yoshihiro Ogawa, Noriko Satoh-Asahara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Thyroid function is strongly associated with obesity. The aim of this study is to investigate whether serum free thyroxine (FT4) and/or thyrotropin (TSH) levels are associated with the efficacy of weight reduction therapy in obese patients. We enrolled a total of 283 obese patients and cross-sectionally investigated the association of serum FT4 and/or TSH levels with metabolic features. Furthermore, in 97 obese patients who received 6-month weight reduction therapy, we assessed the relationship of serum FT4 and/or TSH levels to the efficacy of weight reduction therapy. Neither baseline serum FT4 nor TSH levels showed any correlations with body weight (BW) and body mass index (BMI) in these obese patients. However, in 57 obese female patients who underwent weight reduction therapy for six months, serum FT4 levels prior to the therapy was negatively correlated with the degrees of reduction of BW (r = -0.354, p = 0.007) and BMI (r = -0.373, p = 0.004). The correlation between baseline serum FT4 levels with the efficacy of weight reduction therapy was not observed in obese male or postmenopausal female patients. This study demonstrates that baseline serum FT4 levels are associated with weight reduction in obese female premenopausal patients. Therefore, baseline FT4 levels can be used as a clinical, noninvasive, hormonal predictor of weight reduction efficacy in obese patients.

Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalEndocrine Journal
Volume63
Issue number3
DOIs
Publication statusPublished - Mar 31 2016
Externally publishedYes

Fingerprint

Thyroxine
Weight Loss
Serum
Therapeutics
Body Mass Index
Body Weight
Thyrotropin
Thyroid Gland
Obesity

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Hashimoto, K., Tagami, T., Yamakage, H., Muranaka, K., Tanaka, M., Odori, S., ... Satoh-Asahara, N. (2016). Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients. Endocrine Journal, 63(3), 221-229. https://doi.org/10.1507/endocrj.EJ15-0498

Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients. / Hashimoto, Koshi; Tagami, Tetsuya; Yamakage, Hajime; Muranaka, Kazuya; Tanaka, Masashi; Odori, Shinji; Kono, Shigeo; Shimatsu, Akira; Ogawa, Yoshihiro; Satoh-Asahara, Noriko.

In: Endocrine Journal, Vol. 63, No. 3, 31.03.2016, p. 221-229.

Research output: Contribution to journalArticle

Hashimoto, K, Tagami, T, Yamakage, H, Muranaka, K, Tanaka, M, Odori, S, Kono, S, Shimatsu, A, Ogawa, Y & Satoh-Asahara, N 2016, 'Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients', Endocrine Journal, vol. 63, no. 3, pp. 221-229. https://doi.org/10.1507/endocrj.EJ15-0498
Hashimoto, Koshi ; Tagami, Tetsuya ; Yamakage, Hajime ; Muranaka, Kazuya ; Tanaka, Masashi ; Odori, Shinji ; Kono, Shigeo ; Shimatsu, Akira ; Ogawa, Yoshihiro ; Satoh-Asahara, Noriko. / Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients. In: Endocrine Journal. 2016 ; Vol. 63, No. 3. pp. 221-229.
@article{6eabc14ff6af42cdb7fd55484248e9d2,
title = "Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients",
abstract = "Thyroid function is strongly associated with obesity. The aim of this study is to investigate whether serum free thyroxine (FT4) and/or thyrotropin (TSH) levels are associated with the efficacy of weight reduction therapy in obese patients. We enrolled a total of 283 obese patients and cross-sectionally investigated the association of serum FT4 and/or TSH levels with metabolic features. Furthermore, in 97 obese patients who received 6-month weight reduction therapy, we assessed the relationship of serum FT4 and/or TSH levels to the efficacy of weight reduction therapy. Neither baseline serum FT4 nor TSH levels showed any correlations with body weight (BW) and body mass index (BMI) in these obese patients. However, in 57 obese female patients who underwent weight reduction therapy for six months, serum FT4 levels prior to the therapy was negatively correlated with the degrees of reduction of BW (r = -0.354, p = 0.007) and BMI (r = -0.373, p = 0.004). The correlation between baseline serum FT4 levels with the efficacy of weight reduction therapy was not observed in obese male or postmenopausal female patients. This study demonstrates that baseline serum FT4 levels are associated with weight reduction in obese female premenopausal patients. Therefore, baseline FT4 levels can be used as a clinical, noninvasive, hormonal predictor of weight reduction efficacy in obese patients.",
author = "Koshi Hashimoto and Tetsuya Tagami and Hajime Yamakage and Kazuya Muranaka and Masashi Tanaka and Shinji Odori and Shigeo Kono and Akira Shimatsu and Yoshihiro Ogawa and Noriko Satoh-Asahara",
year = "2016",
month = "3",
day = "31",
doi = "10.1507/endocrj.EJ15-0498",
language = "English",
volume = "63",
pages = "221--229",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients

AU - Hashimoto, Koshi

AU - Tagami, Tetsuya

AU - Yamakage, Hajime

AU - Muranaka, Kazuya

AU - Tanaka, Masashi

AU - Odori, Shinji

AU - Kono, Shigeo

AU - Shimatsu, Akira

AU - Ogawa, Yoshihiro

AU - Satoh-Asahara, Noriko

PY - 2016/3/31

Y1 - 2016/3/31

N2 - Thyroid function is strongly associated with obesity. The aim of this study is to investigate whether serum free thyroxine (FT4) and/or thyrotropin (TSH) levels are associated with the efficacy of weight reduction therapy in obese patients. We enrolled a total of 283 obese patients and cross-sectionally investigated the association of serum FT4 and/or TSH levels with metabolic features. Furthermore, in 97 obese patients who received 6-month weight reduction therapy, we assessed the relationship of serum FT4 and/or TSH levels to the efficacy of weight reduction therapy. Neither baseline serum FT4 nor TSH levels showed any correlations with body weight (BW) and body mass index (BMI) in these obese patients. However, in 57 obese female patients who underwent weight reduction therapy for six months, serum FT4 levels prior to the therapy was negatively correlated with the degrees of reduction of BW (r = -0.354, p = 0.007) and BMI (r = -0.373, p = 0.004). The correlation between baseline serum FT4 levels with the efficacy of weight reduction therapy was not observed in obese male or postmenopausal female patients. This study demonstrates that baseline serum FT4 levels are associated with weight reduction in obese female premenopausal patients. Therefore, baseline FT4 levels can be used as a clinical, noninvasive, hormonal predictor of weight reduction efficacy in obese patients.

AB - Thyroid function is strongly associated with obesity. The aim of this study is to investigate whether serum free thyroxine (FT4) and/or thyrotropin (TSH) levels are associated with the efficacy of weight reduction therapy in obese patients. We enrolled a total of 283 obese patients and cross-sectionally investigated the association of serum FT4 and/or TSH levels with metabolic features. Furthermore, in 97 obese patients who received 6-month weight reduction therapy, we assessed the relationship of serum FT4 and/or TSH levels to the efficacy of weight reduction therapy. Neither baseline serum FT4 nor TSH levels showed any correlations with body weight (BW) and body mass index (BMI) in these obese patients. However, in 57 obese female patients who underwent weight reduction therapy for six months, serum FT4 levels prior to the therapy was negatively correlated with the degrees of reduction of BW (r = -0.354, p = 0.007) and BMI (r = -0.373, p = 0.004). The correlation between baseline serum FT4 levels with the efficacy of weight reduction therapy was not observed in obese male or postmenopausal female patients. This study demonstrates that baseline serum FT4 levels are associated with weight reduction in obese female premenopausal patients. Therefore, baseline FT4 levels can be used as a clinical, noninvasive, hormonal predictor of weight reduction efficacy in obese patients.

UR - http://www.scopus.com/inward/record.url?scp=84962003797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962003797&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ15-0498

DO - 10.1507/endocrj.EJ15-0498

M3 - Article

C2 - 26632173

AN - SCOPUS:84962003797

VL - 63

SP - 221

EP - 229

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 3

ER -